Related Experiment Video
Updated: Nov 8, 2025
Murine Kidney Transplant Technique
Published on: October 20, 2015
Thrombotic Microangiopathy After Kidney Transplantation: An Underdiagnosed and Potentially Reversible Entity
Ana Ávila1, Eva Gavela1, Asunción Sancho1
1Nephrology Department, University Hospital Dr. Peset, Valencia, Spain.
Abstract:
Thrombotic microangiopathy is a rare but serious complication that affects kidney transplant recipients. It appears in 0.8-14% of transplanted patients and negatively affects graft and patient survival. It can appear in a systemic form, with hemolytic microangiopathic anemia, thrombocytopenia, and renal failure, or in a localized form, with progressive renal failure, proteinuria, or arterial hypertension. Post-transplant thrombotic microangiopathy is classified as recurrent atypical hemolytic uremic syndrome or de novo thrombotic microangiopathy. De novo thrombotic microangiopathy accounts for the majority of cases. Distinguishing between the 2 conditions can be difficult, given there is an overlap between them. Complement overactivation is the cornerstone of all post-transplant thrombotic microangiopathies, and has been demonstrated in the context of organ procurement, ischemia-reperfusion phenomena, immunosuppressive drugs, antibody-mediated rejection, viral infections, and post-transplant relapse of antiphospholipid antibody syndrome. Although treatment of the causative agents is usually the first line of treatment, this approach might not be sufficient. Plasma exchange typically resolves hematologic abnormalities but does not improve renal function. Complement blockade with eculizumab has been shown to be an effective therapy in post-transplant thrombotic microangiopathy, but it is necessary to define which patients can benefit from this therapy and when and how eculizumab should be used.
Insights
Post-transplant thrombotic microangiopathy (TMA) is a serious kidney transplant complication. Complement overactivation drives TMA, and while eculizumab shows promise, patient selection for this therapy requires further definition.
Area of Science:
- Nephrology
- Transplantation Immunology
- Hematology
Background:
- Thrombotic microangiopathy (TMA) affects 0.8-14% of kidney transplant recipients, impacting graft and patient survival.
- TMA presents systemically (hemolytic anemia, thrombocytopenia, renal failure) or locally (renal failure, proteinuria, hypertension).
- Post-transplant TMA includes recurrent atypical hemolytic uremic syndrome and de novo TMA, with the latter being more common.
Purpose of the Study:
- To review the pathophysiology of post-transplant TMA, emphasizing complement overactivation.
- To discuss current treatment limitations and the emerging role of complement inhibition.
- To highlight the need for defining optimal eculizumab use in post-transplant TMA.
Main Methods:
- Literature review of post-transplant thrombotic microangiopathy.
- Analysis of the role of complement pathways in TMA pathogenesis.
- Evaluation of therapeutic strategies including plasma exchange and eculizumab.
Main Results:
- Complement overactivation is central to post-transplant TMA, triggered by various factors like ischemia-reperfusion and immunosuppression.
- Plasma exchange improves hematologic parameters but not renal function in TMA.
- Eculizumab demonstrates efficacy in treating post-transplant TMA, suggesting a role for complement blockade.
Conclusions:
- Post-transplant TMA is a complex complication driven by complement dysregulation.
- Current treatments have limitations, necessitating novel therapeutic approaches.
- Further research is needed to identify patient subgroups who will benefit from eculizumab and to optimize its administration.
Related Concept Videos
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:29Acute Kidney Injury II: Pathophysiology
01:24Nephrotic Syndrome I : Introduction
01:29Acute Kidney Injury III: Clinical Manifestations
01:16Kidney Transplant III: Nursing Management
01:26Kidney Transplant II: Surgical Procedure